A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease

被引：217
作者：
Karran, Eric [1 ,2 ,3 ]
Hardy, John [2 ,3 ]
机构：
[1] Alzheimers Res UK, Cambridge CB21 6AD, England
[2] Reta Lila Weston Labs, London, England
[3] UCL, Dept Mol Neurosci, London, England
来源：
ANNALS OF NEUROLOGY | 2014年 / 76卷 / 02期
基金：
英国惠康基金;
关键词：
GAMMA-SECRETASE INHIBITOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSGENIC MOUSE MODEL; BETA IN-VIVO; A-BETA; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; R-FLURBIPROFEN; PEPTIDE; IMMUNIZATION;
D O I：
10.1002/ana.24188
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：185 / 205
页数：21
相关论文
共 134 条
  • [1] Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition
    Abramowski, Dorothee
    Wiederhold, Karl-Heinz
    Furrer, Ulrich
    Jaton, Anne-Lise
    Neuenschwander, Anton
    Runser, Marie-Josephine
    Danner, Simone
    Reichwald, Julia
    Ammaturo, Domenico
    Staab, Dieter
    Stoeckli, Markus
    Rueeger, Heinrich
    Neumann, Ulf
    Staufenbiel, Matthias
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (02) : 411 - 424
  • [2] A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
    Aisen, P. S.
    Saumier, D.
    Briand, R.
    Laurin, J.
    Gervais, F.
    Tremblay, P.
    Garceau, D.
    [J]. NEUROLOGY, 2006, 67 (10) : 1757 - 1763
  • [3] Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
    Aisen, Paul S.
    Gauthier, Serge
    Ferris, Steven H.
    Saumier, Daniel
    Haine, Denis
    Garceau, Denis
    Anh Duong
    Suhy, Joyce
    Oh, Joonmi
    Lau, Wan C.
    Sampalis, John
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2011, 7 (01) : 102 - 111
  • [4] Alzheimer A., 1907, Zentrabl, Nervenheilk., V30, P177
  • [5] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
    Andreasen, N
    Hesse, C
    Davidsson, P
    Minthon, L
    Wallin, A
    Winblad, B
    Vanderstichele, H
    Vanmechelen, E
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
  • [6] Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
    Arvanitakis, Z.
    Grodstein, F.
    Bienias, J. L.
    Schneider, J. A.
    Wilson, R. S.
    Kelly, J. F.
    Evans, D. A.
    Bennett, D. A.
    [J]. NEUROLOGY, 2008, 70 (23) : 2219 - 2225
  • [7] Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease
    Bacher, Michael
    Depboylu, Candan
    Du, Yansheng
    Noelker, Carmen
    Oertel, Wolfgang H.
    Behr, Thomas
    Henriksen, Gjermund
    Behe, Martin
    Dodel, Richard
    [J]. NEUROSCIENCE LETTERS, 2009, 449 (03) : 240 - 245
  • [8] Bacskai BJ, 2002, J NEUROSCI, V22, P7873
  • [9] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
    Bard, F
    Cannon, C
    Barbour, R
    Burke, RL
    Games, D
    Grajeda, H
    Guido, T
    Hu, K
    Huang, JP
    Johnson-Wood, K
    Khan, K
    Kholodenko, D
    Lee, M
    Lieberburg, I
    Motter, R
    Nguyen, M
    Soriano, F
    Vasquez, N
    Weiss, K
    Welch, B
    Seubert, P
    Schenk, D
    Yednock, T
    [J]. NATURE MEDICINE, 2000, 6 (08) : 916 - 919
  • [10] Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
    Bard, Frederique
    Fox, Michael
    Friedrich, Stuart
    Seubert, Peter
    Schenk, Dale
    Kinney, Gene G.
    Yednock, Ted
    [J]. EXPERIMENTAL NEUROLOGY, 2012, 238 (01) : 38 - 43
12345678910